Pos0808 Drug Survival in Spondyloarthritis: Anti-Il17 Outperforms Anti-TNF in First Biologic Treatment

Background: Objectives: Drug survival rates serve as key indicators for assessing both the efficacy and safety of treatments in real life setting. Our aim was to compare the drug retention of first line biologics, anti-tumor necrosis factor (anti-TNF) therapies or anti-interleukin 17 (anti-IL17) therapies. Methods: This retrospective cohort study, using data from the French National Health Data System (SNDS), included adult patients diagnosed with Spondyloarthritis (SpA), encompassing axial SpA (axSpA) and Psoriatic Arthritis (PsA), who initiated a first biologic, either anti-TNF or anti-IL17 agent, between January 1, 2015, and December 31, 2018. Follow-up extended until December 31, 2020. The timeframe considered was chosen based on the market release of drugs and to ensure a follow-up of at least 2 years preceding the COVID-19 pandemic period, potential bias on drug survival. Drug survival was described with Kaplan-Meier curves, and predictive factors were identified with a multivariable Cox model adjusted for age, gender, calendar initiation period, and potential indication modifiers such as multiple sclerosis, heart failure, psoriasis, and cancer. Results: Of the 26,992 SpA patients initiating a first anti-TNF (n = 26,039) or a first anti-IL17 (n = 953), with a median age at initiation of 44.5 years ± 13.1 and 56.2% female, 25,553 (95.0%) had a diagnosis of axSpA, and 5,453 (20.2%) had PsA. In the entire population, the median drug survival was 13.2 months (CI95 %: 12.8–13.6) for anti-TNF and 18.3 months (CI95 %: 16.2–21.1) for anti-IL17. The retention rates at 1 and 2 years were 52.3% (51.7-53.0) and 37.4% (36.9-38.0) with anti-TNF, compared to 60.6% (57.6-63.8) and 43.6% (40.5-46.9) with anti-IL17. In the axSpA population, the median drug survival was 13.2 months (CI95 %: 12.9–13.7) for anti-TNF and 18.3 months (CI95 %: 19.0–21.5) for anti-IL17 (adjusted HR = 0.83 0.76-0.91, p Conclusion: Cohort study of 26,992 patients with SpA initiating a first biologic demonstrated better drug retention with anti-IL17 compared to anti-TNF. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: Thao Pham Abbvie, Amgen, Biogen, Celgene, Celltrion, Fresenius-Kabi, Galapagos, Janssen, Lilly, MSD, Nordic, Novartis, Pfizer, Roche-Chugai, Sandoz, Sanofi, UCB, Raphaelle Curmin: None declared, Benoît Flachaire: None declared, Sandrine Pinto: None declared, Florence Tubach: None declared, Corinne Miceli Richard: None declared.